Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of sublingual S90098 in outpatients with major depressive disorder
2007-003312-65Phase 2Completed
- Sponsor
- Servier
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of agomelatine in major depressive disorder (MDD) (3 arms), sponsored by Servier. Primary endpoint: HAM-D 17-item total score change. Started Oct 2007; status: completed.
02
Drugs
agomelatine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2007-003312-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003312-65.